Manuscript
Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial
Ivan Koychev et al.
Alzheimers Res Ther. 2024;16:212
Manuscript
Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial
Abderrahim Oulhaj et al.
Diabetes Obes Metab. 2024;26:4602-4612
Manuscript
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management
Ni Gao et al.
PharmacoEconomics 2024;42:1017-1028
Manuscript
Post-trial Monitoring of a Randomised Controlled Trial of Intensive Glycaemic Control in Type 2 Diabetes Extended from 10 to 24 years (UKPDS 91)
Amanda I. Adler et al.
Lancet 2024;404:145-55
Manuscript
Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data
Patrick Bidulka et al.
BMJ 2024;10
Manuscript
Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? insights from post-hoc analysis of EXSCEL,
K.M. Gooding et al.
Diabetes Res Clin Pract. 2024;212:111685